| VEI (-) N = 1,414 (25.8%) | VEI (+) N = 4,068 (74.2%) | Univariate analysis (P value)* |
---|---|---|---|
Age in years (SD) | 73.6 (11.8) | 72.9 (11.7) | 0.045 |
Gender (female) | 40.2% | 39.5% | 0.614 |
mRS pre-admission | Â | Â | Â |
   mRS = 0 | 61.7% | 65.3% |  |
   mRS = 1 | 19.7% | 19.0% | 0.007 |
   mRS = 2 | 8.6% | 8.4% |  |
   mRS = 3 | 10.0% | 7.3% |  |
Functional severity score, mean (SD) ¶ | 0.24 (1.78) | 0.10 (1.69) | 0.005 |
Functional capability score, mean (SD) ¶ | -0.12 (1.1) | -0.29 (0.99) | < 0.001 |
Co-morbidity index (CI > 1) | 48.4% | 49.2% | 0.629 |
Use of edaravone | 56.5% | 59.8% | 0.032 |
Training intensity (unit/day), mean (SD) | 1.04 (0.84) | 1.71 (1.25) | < 0.001 |
mRS at discharge (0-1) | 40.1% | 45.3% | < 0.001 |
In-hospital mortality | 1.7% | 1.6% | 0.799 |
Friday admission | 23.9% | 12.1% | < 0.001 |